These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33429746)

  • 1. Efficacy of treatment for acneiform eruptions related to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC): A protocol of systematic review and network meta-analysis.
    He C; Lin R; Zhang J; Sun L; Lin J; Lin L
    Medicine (Baltimore); 2021 Jan; 100(1):e23875. PubMed ID: 33429746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of EGFR Tyrosine Kinase Inhibitors Combined with Cranial Radiotherapy for Brain Metastases from Non-Small-Cell Lung Cancer: A Protocol for a Systematic Review and Meta-Analysis.
    Ge Y; Xu B; Wang H; Gao J; Zhang X; Lu T; Gao R; Li J
    Biomed Res Int; 2022; 2022():6531748. PubMed ID: 35872868
    [No Abstract]   [Full Text] [Related]  

  • 3. A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors.
    Bierbrier R; Lam M; Pehr K
    Dermatol Ther; 2022 May; 35(5):e15412. PubMed ID: 35220635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients: A network meta-analysis.
    Wu Z; Chen S; Du X; Wu Y; Xie X
    J Clin Pharm Ther; 2021 Apr; 46(2):310-318. PubMed ID: 33031574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis.
    Gorji M; Joseph J; Pavlakis N; Smith SD
    Asia Pac J Clin Oncol; 2022 Dec; 18(6):526-539. PubMed ID: 35352492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
    Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
    Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.
    Chen Y; Wen S; Wu Y; Shi L; Xu X; Shen B
    Crit Rev Oncol Hematol; 2021 Jul; 163():103393. PubMed ID: 34119658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.
    Xu Z; Liu C; Zhu Y; Zou Z; Xie T; Xing P; Wang L; Li J
    BMC Cancer; 2022 May; 22(1):514. PubMed ID: 35525919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
    Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
    Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials.
    Yin Q; Xun X; Yang G; Cui H; Liu H
    Oncol Res Treat; 2021; 44(6):344-353. PubMed ID: 33951671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
    Sheng Z; Zhang Y
    Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis.
    Yuan JQ; Zhang YL; Li HT; Mao C
    Medicine (Baltimore); 2017 Feb; 96(7):e6151. PubMed ID: 28207548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
    Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J
    BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non- small-cell lung cancer: a meta-analysis of randomized controlled trials.
    Alimujiang S; Zhang T; Han ZG; Yuan SF; Wang Q; Yu TT; Shan L
    Asian Pac J Cancer Prev; 2013; 14(4):2413-9. PubMed ID: 23725150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe EGFR inhibitor-induced acneiform eruption responding to dapsone.
    Beshay A; Petersen M; Rhoads JLW
    Dermatol Online J; 2021 Jul; 27(7):. PubMed ID: 34391331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.
    Yang F; Zhang W; Shang X; Liu N; Ma X; Qin J; Zhang Y; Liu Y; Wang X
    Crit Rev Oncol Hematol; 2022 Sep; 177():103760. PubMed ID: 35870763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.